resiquimod
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines. In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, and an upregulator of the opioid growth factor receptor. On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma. — Wikipedia
Clinical trial activity
21 trials · 16 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2004 (NCT00114920)
Timeline
Indications
Studied for
- Astrocytoma · Phase 2
- Basal Cell Carcinoma · Phase 1/Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Hepatitis B · Phase 1/Phase 2
- Influenza Vaccines · Phase 1
- Keratosis, Actinic · Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, T-Cell, Cutaneous · Phase 2
- Melanoma · Phase 2
- Neoplasms · Phase 1
- Oligodendroglioma · Phase 2
- Prostatic Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Warts · Phase 2
Mechanism of action
- Toll-like receptor 7AGONIST
Toll-like receptor 7 agonist
- Toll-like receptor 8AGONIST
Toll-like receptor 8 agonist
Chemistry & pharmacology
SMILES
CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O- Mol. weight
- 314.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaResiquimod ↗
- ChEMBLCHEMBL383322 ↗
Also known as
- r848
- r848
- r 848
- r-848
- r848 compound
- resiquimod
- resiquimod
- resiquimod
- resiquimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06450106 | Phase 1 | Sep 30, 2024 | SURGE Therapeutics |
| NCT05710848 | Phase 1/Phase 2 (Phase 2) | Jul 11, 2023 | Baylor University, SURGE Therapeutics |
| NCT03292406 | Phase 2 | Dec 19, 2017 | Galderma |
| NCT02126579 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2014 | University of Virginia |
| NCT01737580 | Phase 1 | Apr 1, 2013 | University of British Columbia |
| NCT01808950 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2013 | Spirig Pharma Ltd. |
| NCT01748747 | N/A | Oct 1, 2012 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT01583816 | Phase 2 | May 1, 2012 | Spirig Pharma Ltd., University of Zurich |
| NCT01676831 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | University of Pennsylvania |
| NCT01204684 | Phase 2 | Sep 1, 2010 | University of California, Los Angeles |
| NCT00960752 | Phase 2 | May 1, 2010 | University of Texas at Houston |
| NCT00948961 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2009 | Celldex Therapeutics |
| NCT00821652 | Phase 1 | Feb 1, 2009 | Cancer Research Institute, Icahn School of Medicine at Mount Sinai |
| NCT00470379 | Early Phase 1 (Phase 1) | Apr 1, 2006 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00175435 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2005 | University of British Columbia |
| NCT00116675 | Phase 2 | Mar 1, 2005 | Graceway |
| NCT00116662 | Phase 2 | Mar 1, 2005 | Graceway |
| NCT00117871 | Phase 2 | Oct 1, 2004 | Graceway |
| NCT00117923 | Phase 2 | Aug 1, 2004 | Graceway |
| NCT00115141 | Phase 2 | Apr 1, 2004 | Graceway |
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Graceway | For profit | 6 | 6 | 1 | 2004 |
| Mayo Clinic | Academic/Hospital | 2 | 2 | 2 | 2006 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2006 |
| Spirig Pharma Ltd. | For profit | 2 | 2 | 1 | 2012 |
| SURGE Therapeutics | For profit | 2 | 2 | 2 | 2023 |
| University of British Columbia | Academic/Hospital | 2 | 2 | 2 | 2005 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Celldex Therapeutics | For profit | 1 | 1 | 1 | 2009 |
| Galderma | For profit | 1 | 1 | 1 | 2017 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Zurich | Academic/Hospital | 1 | 0 | 1 | 2012 |